NEW YORK (GenomeWeb) – Cancer Genetics (CGI) announced today that it has partnered with the Bio Analytical Research Corporation (BARC) to jointly offer their services to biotech and pharmaceutical companies.
The partners will offer access to BARC's network of global central labs in combination with CGI's expertise in biomarker and genomic testing, and in the development of companion diagnostic development for oncology.
BARC has seven clinical labs, and manages the laboratory component of Phase I through Phase IV clinical trials for the pharma industry, CGI said. The two companies will market, sell, and deliver on contracts for validated biomarkers and companion diagnostics for oncology trials. The offerings will range from oncology-focused genomic testing to core central laboratory analysis, project and data management, and the transportation of samples.
"We are very excited about this partnership, as this will help our customers on a global basis to accelerate their drug development and incorporate the additional biomarker and genomic data needed to improve decision making," BARC CEO Michel Abiteboul said in a statement. "CGI will enable BARC to offer world-class genomics expertise to make early decisions in the complex field of oncology, especially in the very competitive environment of immuno-oncology."
CGI CEO Panna Sharma added that the partnership will support the development of personalized medicine, and "will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating CGI's specialized genomic testing with BARC's laboratory solutions and global network."